The cannabis-compound cannabidiol (CBD) is a promising option for treating refractory epilepsy in pediatric patients, according to a new study.
The study, titled “Use of Cannabidiol in the Treatment of Drug-Refractory Epilepsy in Children and Young Adults: A Systematic Review”, was conducted by researchers at the Rafael Nuñez University Corporation in Colombia and published in the Journal of Neurosciences in Rural Practice. It was also epublished by the National Library of Medicine.
According to the study “Epilepsy poses a significant challenge in pediatric and adolescent populations, impacting not only seizures but also psychological and cognitive comorbidities, leading to higher mortality rates than the general population”. It notes that “Drug-refractory epilepsy, resistant to conventional treatments, affects a range of 7-20% of pediatric patients. The search for alternative therapies has led to exploring the therapeutic potential of Cannabis sativa L. compounds, particularly cannabidiol (CBD).”
Continue reading